{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:24:23Z","timestamp":1790393063730,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100016724","name":"PGIMER","doi-asserted-by":"crossref","award":["9719-126"],"award-info":[{"award-number":["9719-126"]}],"id":[{"id":"10.13039\/100016724","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00259-025-07203-4","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T23:43:23Z","timestamp":1742687003000},"page":"3618-3631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploring currently available fibroblast activation protein targeting molecules in adrenocortical carcinoma: Navigating theranostic pathways"],"prefix":"10.1007","volume":"52","author":[{"given":"Sejal","family":"Chopra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3355-4168","authenticated-orcid":false,"given":"Jaya","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyavrat","family":"Purohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umanath","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Roesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euy Sung","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivedita","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay Kumar","family":"Bhadada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagwant Rai","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"Walia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"issue":"7","key":"7203_CR1","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1210\/jc.2005-2730","volume":"91","author":"G Abiven","year":"2006","unstructured":"Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006;91(7):2650\u20135.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"7203_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrendo.2010.235","volume":"7","author":"M Fassnacht","year":"2011","unstructured":"Fassnacht M, Lib\u00e9 R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician\u2019s update. Nat Rev Endocrinol. 2011;7(6):323\u201335.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"7203_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.21037\/amj.2020.01.07","volume":"5","author":"JE Hallanger-Johnson","year":"2020","unstructured":"Hallanger-Johnson JE. Systemic therapy for adrenocortical carcinoma: a review. AME Med J. 2020;5(5):5.","journal-title":"AME Med J"},{"key":"7203_CR4","doi-asserted-by":"publisher","first-page":"613248","DOI":"10.3389\/fendo.2021.613248","volume":"12","author":"G Alyateem","year":"2021","unstructured":"Alyateem G, Nilubol N. Current status and future targeted therapy in adrenocortical cancer. Front Endocrinol. 2021;12:613248.","journal-title":"Front Endocrinol"},{"key":"7203_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1097\/JTO.0000000000000149","volume":"9","author":"HM Karvonen","year":"2014","unstructured":"Karvonen HM, Lehtonen ST, Sormunen RT, Lappi-Blanco E, Sk\u00f6ld CM, Kaarteenaho RL. Lung cancer\u2013associated myofibroblasts reveal distinctive ultrastructure and function. J Thorac Oncol. 2014;9:664\u201374.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"7203_CR6","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1096\/fj.13-236828","volume":"28","author":"S Karki","year":"2014","unstructured":"Karki S, Surolia R, Hock TD, Guroji P, Zolak JS, Duggal R, et al. Wilms\u2019 tumor 1 (Wt1) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in idiopathic pulmonary fibrosis. FASEB J. 2014;28(3):1122\u201331.","journal-title":"FASEB J"},{"key":"7203_CR7","doi-asserted-by":"publisher","first-page":"658","DOI":"10.4149\/neo_2012_083","volume":"59","author":"H Shu","year":"2012","unstructured":"Shu H, Li HF. Prognostic effect of stromal myofibroblasts in lung adenocarcinoma. Neoplasma. 2012;59:658\u201361.","journal-title":"Neoplasma"},{"key":"7203_CR8","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrc1877","volume":"6","author":"R Kalluri","year":"2006","unstructured":"Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392\u2013401.","journal-title":"Nat Rev Cancer"},{"issue":"5570","key":"7203_CR9","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1126\/science.1067431","volume":"296","author":"BS Wiseman","year":"2002","unstructured":"Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. Science. 2002;296(5570):1046\u20139.","journal-title":"Science"},{"issue":"32","key":"7203_CR10","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1038\/s41388-018-0275-3","volume":"37","author":"E Pur\u00e9","year":"2018","unstructured":"Pur\u00e9 E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene. 2018;37(32):4343\u201357.","journal-title":"Oncogene"},{"key":"7203_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1158\/1535-7163.MCT-11-0340","volume":"11","author":"WN Brennen","year":"2012","unstructured":"Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein- expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012;11:257\u201366.","journal-title":"Mol Cancer Ther"},{"issue":"18","key":"7203_CR12","doi-asserted-by":"publisher","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","volume":"87","author":"P Garin-Chesa","year":"1990","unstructured":"Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA. 1990;87(18):7235\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"7203_CR13","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.3390\/cancers7040902","volume":"7","author":"K Shiga","year":"2015","unstructured":"Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Takeyama H. Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers. 2015;7(4):2443\u201358.","journal-title":"Cancers"},{"issue":"19","key":"7203_CR14","doi-asserted-by":"publisher","first-page":"6005","DOI":"10.1021\/jm800390n","volume":"51","author":"BA Connolly","year":"2008","unstructured":"Connolly BA, Sanford DG, Chiluwal AK, Healey SE, Peters DE, Dimare MT, et al. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety. J Med Chem. 2008;51(19):6005\u201313.","journal-title":"J Med Chem"},{"issue":"9","key":"7203_CR15","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1021\/jm400351a","volume":"56","author":"SE Poplawski","year":"2013","unstructured":"Poplawski SE, Lai JH, Li Y, Jin Z, Liu Y, Wu W, et al. Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. J Med Chem. 2013;56(9):3467\u201377.","journal-title":"J Med Chem"},{"issue":"9","key":"7203_CR16","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","volume":"59","author":"A Loktev","year":"2018","unstructured":"Loktev A, Lindner T, Mier W, Debus J, Altmann A, J\u00e4ger D, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59(9):1423\u20139.","journal-title":"J Nucl Med"},{"issue":"9","key":"7203_CR17","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of Quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415\u201322.","journal-title":"J Nucl Med"},{"issue":"8","key":"7203_CR18","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2967\/jnumed.119.236786","volume":"61","author":"C Meyer","year":"2020","unstructured":"Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, et al. Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med. 2020;61(8):1171\u20137.","journal-title":"J Nucl Med"},{"issue":"1","key":"7203_CR19","first-page":"1","volume":"5","author":"ES Moon","year":"2020","unstructured":"Moon ES, Elvas F, Vliegen G, De Lombaerde S, Vangestel C, De Bruycker S, et al. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators. EJNMMI Res. 2020;5(1):1\u201320.","journal-title":"EJNMMI Res"},{"issue":"8","key":"7203_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/cmdc.201900559","volume":"15","author":"L Greifenstein","year":"2020","unstructured":"Greifenstein L, Engelbogen N, Lahnif H, Sinnes JP, Bergmann R, Bachmann M, et al. Synthesis, labeling and preclinical evaluation of a squaric acid containing PSMA inhibitor labeled with 68Ga: A comparison with PSMA-11 and PSMA-617. ChemMedChem. 2020;15(8):695\u2013704.","journal-title":"ChemMedChem"},{"key":"7203_CR21","doi-asserted-by":"crossref","unstructured":"Chopra S, Walia R, Mathur Y, Roesch F, Moon ES, Rana N, et al. 68Ga-DOTA. SA.FAPI as a potential, noninvasive diagnostic probe for recurrent and metastatic adrenocortical carcinoma: A head-to-head comparison with 18F-FDG. Clin Nucl Med. 2023;48(4):173\u20135.","DOI":"10.1097\/RLU.0000000000004563"},{"key":"7203_CR22","doi-asserted-by":"crossref","unstructured":"Chopra S, Mathur Y, Roesch F, Moon ES, Rana N, Irrinki S, et al. 68Ga-DOTA. SA. FAPi as a versatile diagnostic probe for various epithelial malignancies: A head-to-head comparison with 18F-FDG. Acad Radiol. 2024;31(6):2521\u201335.","DOI":"10.1016\/j.acra.2023.12.002"},{"issue":"10","key":"7203_CR23","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1097\/RLU.0000000000005391","volume":"49","author":"S Chopra","year":"2024","unstructured":"Chopra S, Mathur Y, Roesch F, Moon ES, Singh H, Kalra N, et al. 68 Ga-DOTA.SA.FAPi PET in response assessment after 177 Lu-microspheres selective Intra-arterial radionuclide therapy for unresectable hepatocellular carcinoma. Clin Nucl Med. 2024;49(10):e511\u20132.","journal-title":"Clin Nucl Med"},{"issue":"6","key":"7203_CR24","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s00259-020-05132-y","volume":"48","author":"S Ballal","year":"2021","unstructured":"Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S, et al. Biodistribution, pharmacokinetics, dosimetry of [68Ga] Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F] F-FDG PET\/CT in patients with various cancers. Eur J Nucl Med Mol Imaging. 2021;48(6):1915\u201331.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"7203_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122\u201350.","journal-title":"J Nucl Med"},{"issue":"1","key":"7203_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4103\/aca.ACA_157_18","volume":"22","author":"P Mishra","year":"2019","unstructured":"Mishra P, Pandey CM, Singh U, Gupta A, Sahu C, Keshri A. Descriptive statistics and normality tests for statistical data. Ann Card Anaesth. 2019;22(1):67.","journal-title":"Ann Card Anaesth"},{"issue":"1","key":"7203_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/JTO.0b013e318200f983","volume":"6","author":"JN Mandrekar","year":"2011","unstructured":"Mandrekar JN. Measures of interrater agreement. J Thorac Oncol. 2011;6(1):6\u20137.","journal-title":"J Thorac Oncol"},{"key":"7203_CR28","doi-asserted-by":"crossref","unstructured":"Assie G, Jouinot A, Martin Y, Foulonneau T, Bendjelal Y, Violon F, et al. Single-nucleus atlas of adrenocortical carcinoma reveals tumor ecotypes associated with outcome. InEndocrine Abstracts. 2024;99. Bioscientifica.","DOI":"10.1530\/endoabs.99.OC7.4"},{"issue":"10","key":"7203_CR29","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","volume":"60","author":"A Loktev","year":"2019","unstructured":"Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, et al. Development of fibroblast activation protein\u2013targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60(10):1421\u20139.","journal-title":"J Nucl Med"},{"issue":"9","key":"7203_CR30","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1369\/0022155412453051","volume":"60","author":"TT My\u00f6h\u00e4nen","year":"2012","unstructured":"My\u00f6h\u00e4nen TT, Pyykk\u00f6 E, M\u00e4nnist\u00f6 PT, Carpen O. Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors. J Histochem Cytochem. 2012;60(9):706\u201315.","journal-title":"J Histochem Cytochem"},{"key":"7203_CR31","doi-asserted-by":"crossref","unstructured":"Backhaus P, Gierse F, Burg MC, B\u00fcther F, Asmus I, Dorten P, et al. Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68 Ga] Ga-OncoFAP-DOTAGA. Eur J Nucl Med Mol Imaging. 2022;1\u20131.","DOI":"10.1055\/s-0042-1745972"},{"issue":"6","key":"7203_CR32","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2967\/jnumed.121.262808","volume":"63","author":"L Kessler","year":"2022","unstructured":"Kessler L, Ferdinandus J, Hirmas N, Zarrad F, Nader M, Kersting D, et al. Pitfalls and common findings in 68Ga-FAPI PET: a pictorial analysis. J Nucl Med. 2022;63(6):890\u20136.","journal-title":"J Nucl Med"},{"issue":"3","key":"7203_CR33","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.bbrc.2014.09.096","volume":"453","author":"L Liu","year":"2014","unstructured":"Liu L, Omar B, Marchetti P, Ahr\u00e9n B. Dipeptidyl peptidase-4 (DPP-4): Localization and activity in human and rodent islets. Biochem Biophys Res Commun. 2014;453(3):398\u2013404.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"7203_CR34","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.7150\/thno.86007","volume":"13","author":"R Wang","year":"2023","unstructured":"Wang R, Jakobsson V, Wang J, Zhao T, Peng X, Li B, et al. Dual targeting PET tracer [68Ga] Ga-FAPI-RGD in patients with lung neoplasms: a pilot exploratory study. Theranostics. 2023;13(9):2979.","journal-title":"Theranostics"},{"issue":"6","key":"7203_CR35","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.1097\/RLU.0000000000004601","volume":"48","author":"\u0130 Kaplan","year":"2023","unstructured":"Kaplan \u0130, Can C, Kepenek F, Ibilo\u011flu \u0130, G\u00fczel Y. Superiority of 18F-FDG PET\/CT to 68Ga-FAPI PET\/CT in adrenocortical tumor imaging. Clin Nucl Med. 2023;48(6):e307\u20139.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"7203_CR36","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00259-021-05442-9","volume":"49","author":"F Ding","year":"2021","unstructured":"Ding F, Huang C, Liang C, Wang C, Liu J, Tang D. 68Ga-FAPI-04 vs. 18F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2021;49(1):290\u2013300.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"14","key":"7203_CR37","doi-asserted-by":"publisher","first-page":"7056","DOI":"10.18632\/aging.204892","volume":"15","author":"C Ma","year":"2023","unstructured":"Ma C, Xi S, Sun H, Zhang M, Pei Y. Identifying the oncogenic roles of fap in human cancers based on systematic analysis. Aging (Albany NY). 2023;15(14):7056.","journal-title":"Aging (Albany NY)"},{"key":"7203_CR38","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1007\/s00259-020-05055-8","volume":"48","author":"S Serfling","year":"2021","unstructured":"Serfling S, Zhi Y, Schirbel A, Lindner T, Meyer T, Gerhard-Hart-mann E, et al. Improved cancer detection in Waldeyer\u2019s tonsillar ring by 68Ga-FAPI PET\/CT imaging. Eur J Nucl Med Mol Imaging. 2021;48:1178\u201387.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7203_CR39","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","volume":"47","author":"H Chen","year":"2020","unstructured":"Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47:1820\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"7203_CR40","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1007\/s00259-021-05475-0","volume":"48","author":"M Sollini","year":"2021","unstructured":"Sollini M, Kirienko M, Gelardi F, Fiz F, Gozzi N, Chiti A. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(13):4396\u2013414.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7203_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40658-016-0144-5","volume":"3","author":"M Conti","year":"2016","unstructured":"Conti M, Eriksson L. Physics of pure and non-pure positron emitters for PET: a review and a discussion. EJNMMI physics. 2016;3(1):1\u20137.","journal-title":"EJNMMI physics"},{"key":"7203_CR42","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1245\/s10434-010-1107-z","volume":"17","author":"HY Lee","year":"2010","unstructured":"Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, Shim YM, et al. Volume-based parameter of (18)F-FDG PET\/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol. 2010;17:2787\u201394.","journal-title":"Ann Surg Oncol"},{"key":"7203_CR43","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1245\/s10434-011-2153-x","volume":"19","author":"HH Chung","year":"2012","unstructured":"Chung HH, Kwon HW, Kang KW, Park NH, Song YS, Chung JK, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol. 2012;19:1966\u201372.","journal-title":"Ann Surg Oncol"},{"key":"7203_CR44","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2967\/jnumed.111.099531","volume":"53","author":"EH Dibble","year":"2012","unstructured":"Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med. 2012;53:709\u201315.","journal-title":"J Nucl Med"},{"key":"7203_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00259-011-1934-6","volume":"39","author":"S Liao","year":"2012","unstructured":"Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, et al. Prognostic value of meta-bolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:27\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7203_CR46","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3346\/jkms.2016.31.1.39","volume":"31","author":"JH Hong","year":"2016","unstructured":"Hong JH, Kim HH, Han EJ, Byun JH, Jang HS, Choi EK, et al. Total lesion glycolysis using 18F-FDG PET\/CT as a prognostic factor for locally advanced esophageal cancer. J Korean Med Sci. 2016;31(1):39\u201346.","journal-title":"J Korean Med Sci"},{"issue":"4","key":"7203_CR47","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2967\/jnumed.123.266806","volume":"65","author":"C Li","year":"2024","unstructured":"Li C, Chen Q, Tian Y, Chen J, Xu K, Xiao Z, et al. 68Ga-FAPI-04 PET\/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression. J Nucl Med. 2024;65(4):527\u201332.","journal-title":"J Nucl Med"},{"key":"7203_CR48","unstructured":"McConathy J, Dhawan M, Goenka A, Moy R, Menda Y, Chasen B, et al. 177Lu-FAP-2286 in patients with advanced or metastatic solid tumors: Initial data from a phase 1\/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity (LuMIERE)."},{"issue":"3","key":"7203_CR49","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1097\/RLU.0000000000005483","volume":"50","author":"S Chopra","year":"2025","unstructured":"Chopra S, Walia R, Kaur K, Roesch F, Moon ES, Mittal BR, et al. Exploring the FAP-Targeted Therapeutics for Adrenocortical Carcinoma: Choosing the Right Track. Clin Nucl Med. 2025;50(3):e160\u20133.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"7203_CR50","first-page":"65","volume":"32","author":"S Ballal","year":"2022","unstructured":"Ballal S, Yadav MP, Moon ES, Roesch F, Kumari S, Agarwal S, et al. Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study. Thyroid. 2022;32(1):65\u201377.","journal-title":"Thyroid"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07203-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07203-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07203-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T10:06:37Z","timestamp":1757153197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07203-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7203"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07203-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,22]]},"assertion":[{"value":"5 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Ethics Committee (INT\/IEC\/2021\/SPL-500).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"An informed written consent for participation in the study and publications of clinical data were taken from the patients enrolled in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}